Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same

1) The compounds of formula (I)

• in all their isomeric forms, alone or in mixture, as well as their physiologically acceptable addition salts, in which
• G represents
• R7R8N—C(═NR6)—NH—CO—
• Het-NH—CO—;
• Het-NH—CH2—,
• Het-,
• Het representing a monocyclic or polycyclic system, each ring being constituted by 4 to 10 aromatic or non aromatic members, the ring or at least one of the rings containing 1 to 4 nitrogen atoms, substituted or non substituted by one or more R9 groups
• R1 represents a hydrogen atom;
• a (C5-C14)-aryl;
• (C5-C14)-aryl-(C1-C4)-alkyl-group;
• an amino radical non substituted or monosubstitufedordisubstituted by an alkyl radical and/or an acyl radical containing 1 to 4 carbon atoms;
• R2 represents a hydrogen atom;
• a halogen atom;
• a nitro group;
• an alkyl radical containing 1 to 4 carbon atoms;
• an amino radical non substituted or monosubstituted or disubstituted by an alkyl radical and/or an acyl radical containing 1 to 4 carbon atoms;
• a-(CH2)0-2—CO2R5 group;
• or a —(CH2)0-2—OR5 group;
• R3 represents
• a hydrogen atom
• a-CO2R5 radical,
• a-SO2R5 radical or
• a monocyclic or polycyclic system, each ring being constituted by 4 to 10 aromatic or non aromatic members, the ring or at least one of the rings containing 1 to 4 heteroatoms chosen from N, O or S, substituted or non substituted by one or more R9 radicals,
• R4 represents OH;
• (C1-C8)-alkoxy-;
• (C5-C14)-aryl-(C1-C4)-alkyloxy-;
• (C5-C14)-aryloxy-;
• (C3-C12)-cycloalkyloxy;
• (C3-C12)-cycloalkyl-(C1-C4)-alkyloxy-;
• (C1-C8)-alkylcarbonyloxy-(C1-C4)-alkyloxy-;
• (C5-C14)-aryl-(C 1-C4)-alkylcarbonyloxy-(C1-C4) alkyloxy-;
• (C1-C8)dialkylaminocarbonylmethyloxy-;
• (C5-C14)-aryl-(C1-C4)-dialkylaminocarbonylmethyloxy-;
• an amino radical non substituted or monosubstituted or disubstituted by a (C1-C4)-alkyl and/or (C5-C14)-aryl and/or (C5-C14)-aryl-(C1-C4)-alkyl- radical and/or a (C1-C5)-acyl radical;
• or the remainder of an amino acid D or L;
• R5 represents (C1-C8)-alkyl;
• (C5-C14)-aryl;
• (C5-C14)-aryl-(C1-C4)-alkyl-;
• (C3-C12)-cycloalkyl or (C3-C12)-cycloalkyl-(C1-C4)-alkyl-, bicycloalkyl-(C1-C4)-alkyl-, tricycloalkyl-(C1-C4)-alkyl-, the said aryl, alkyl, cycloalkyl, bicycloalkyl and tricycloalkyl radicals being non substituted or substituted by one or more chosen R9 groups;
• R represents a hydrogen atom;
• a hydroxyl;
• nitro, (C1-C6)-alkyl-O—CO—;
• or (C1-C6)-alkyl-O—CO—O— group:
• R7 and R8, independently of one another represent a hydrogen atom or a (C1-C6)-alkyl radical non substituted or substituted by R9;
• R9 represents halogen;
• amino ;
• nitro ;
• hydroxyl, (C1-C4)-alkyloxy-;
• (C1-C4)-alkylthio-;
• carboxy;
• (C1-C4)-alkyloxycarbonyl-;
• (C1-C8)-alkyl non substituted or substituted by one or more halogen atoms, (C5-C14)-aryl, (C5-C,4)-aryl-(C1-C4)-alkyl-
• it being understood that the aryl radicals can be non substituted or substituted by one or more identical or different radicals chosen from (C1-C8)-alkyl, in particular (C1-C4)-alkyl, hydroxyl, (C1-C8)-alkyloxy, (C1-C8)-alkylthio, halogen chosen from fluorine, chlorine and bromine, nitro, amino, (C1-C4)-alkylamino, di-(C1-C4)-alkylamino, trifluoromethyl, methylenedioxy, cyano, aminocarbonyl, (C1-C4)-alkylaminocarbonyl, di-(C1-C4)-alkylaminocarbonyl, carboxy, (C1-C4)-alkoxycarbonyl, phenyl, phenoxy, benzyl and benzyloxy.